SpyGlass Pharma (SGP) Common Equity (2024 - 2026)
SpyGlass Pharma (SGP) posted quarterly Common Equity of -$98.8 million for Q4 2025, down 63.44% year-over-year from -$270.3 million in Q4 2024, and down 63.44% quarter-over-quarter from -$60.5 million in Q4 2024.
Powered by 
Analysis
SpyGlass Pharma (SGP) Common Equity (2024 - 2026) Analysis & Trends
SpyGlass Pharma (SGP) has reported Common Equity for 2 consecutive years, with -$98.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Common Equity fell 63.44% year-over-year to -$98.8 million; the TTM figure through Dec 2025 stood at -$98.8 million (down 63.44% YoY), while the FY2025 annual figure was -$98.8 million, down 63.44% from the prior year.
- Common Equity retreated to -$98.8 million in Q4 2025 per SGP's latest filing, from -$60.5 million in the prior quarter.
- Across five years, Common Equity topped out at -$60.5 million in Q4 2024 and bottomed at -$98.8 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.42 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 6.76 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.61 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.17 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.79 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 757.49 Mn |
| 10 | SpyGlass Pharma | 973.76 Mn | 973.76 Mn | - | 232.36 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 232.36 Mn |
| Dec 31, 2025 | -98.84 Mn |
| Jun 30, 2025 | -78.38 Mn |
| Dec 31, 2024 | -60.47 Mn |